A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer
G. Konecny, N. Finkler, P. Lee, A. Yovine, A. Liu, P. Sen, M. Squires, A. KayVolume:
125
Year:
2012
Language:
english
Pages:
1
DOI:
10.1016/j.ygyno.2011.12.192
File:
PDF, 59 KB
english, 2012